Teleflex Incorporated (TFX)
NYSE: TFX · Real-Time Price · USD
139.85
+3.59 (2.63%)
Mar 7, 2025, 4:00 PM EST - Market closed
Teleflex Revenue
In the year 2024, Teleflex had annual revenue of $3.05B with 2.45% growth. Teleflex had revenue of $795.41M in the quarter ending December 31, 2024, with 2.78% growth.
Revenue (ttm)
$3.05B
Revenue Growth
+2.45%
P/S Ratio
2.15
Revenue / Employee
$216,122
Employees
14,100
Market Cap
6.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.05B | 72.84M | 2.45% |
| Dec 31, 2023 | 2.97B | 183.45M | 6.57% |
| Dec 31, 2022 | 2.79B | -18.52M | -0.66% |
| Dec 31, 2021 | 2.81B | 272.41M | 10.74% |
| Dec 31, 2020 | 2.54B | -58.21M | -2.24% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
TFX News
- 2 days ago - DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 - PRNewsWire
- 3 days ago - TFX INVESTOR INVESTIGATION: A Securities Fraud Investigation has been started on behalf of Teleflex Incorporated Investors – Contact BFA Law before the April 23 Court Deadline - GlobeNewsWire
- 5 days ago - TFX INVESTOR NOTICE: Teleflex Incorporated Investors are Notified of Pending Securities Fraud Investigation - Contact BFA Law if You Suffered Losses - Accesswire
- 5 days ago - Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion - Business Wire
- 6 days ago - TFX INVESTIGATION: A Securities Fraud Investigation into Teleflex Incorporated has been Initiated - Investors with Losses are Urged to Contact BFA Law - Accesswire
- 7 days ago - Teleflex's Bold Transformation: Why I'm Skeptical On Value Creation - Seeking Alpha
- 7 days ago - TFX REMINDER: Teleflex Incorporated is Being Investigated for Securities Fraud; Shareholders are Alerted to Contact BFA Law (NYSE:TFX) - GlobeNewsWire
- 9 days ago - TFX STOCK UPDATE: The Teleflex Incorporated Securities Fraud Investigation is Ongoing; Investors are Urged to Contact BFA Law if they Suffered Losses - Accesswire